That includes reviewing the available evidence, clarifying what is known and unknown, outlining regulatory and sporting implications in Australia, and discussing potential risks
In August 2025, Eli Lilly and Company announced positive topline results from the Phase III ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes
Inflammation grading was carried out independently by 3 researchers according to established protocols (77) and to the following scale: 0= No inflammation, 1= small pockets of cellular infiltrations, 2= small pockets of infiltrations less than 3 cells deep surrounding more than one airway or blood vessel, 3= infiltrations more than 3 cells deep found surrounding more than one but less than 50% of the total airways, 4=most airways surrounded by significant immune cell infiltrations, 5= the majority of airways are surrounded by significant immune cell infiltrations which also are seen present in alveolar beds
Several other medications are already approved to treat alcohol use disorder, so until larger studies can confirm the findings, people should talk to their doctor about what's already available, said lead author Christian Hendershot, an addiction researcher at the University of Southern California in the US
Deng, F., Sharma, I., Dai, Y., Yang, M
Try: Brisk walking Cycling Swimming Light strength training Even 30 minutes of moderate exercise most days of the week can significantly support natural GLP 1 boosters in your body
